233 related articles for article (PubMed ID: 33799784)
1. Pancreatic Cancer Meets Human Microbiota: Close Encounters of the Third Kind.
Arsenijevic T; Nicolle R; Bouchart C; D'Haene N; Demetter P; Puleo F; Van Laethem JL
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33799784
[TBL] [Abstract][Full Text] [Related]
2. The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma.
Ciernikova S; Novisedlakova M; Cholujova D; Stevurkova V; Mego M
Biomedicines; 2020 Dec; 8(12):. PubMed ID: 33287196
[TBL] [Abstract][Full Text] [Related]
3. The role of microbiome in pancreatic cancer.
Li JJ; Zhu M; Kashyap PC; Chia N; Tran NH; McWilliams RR; Bekaii-Saab TS; Ma WW
Cancer Metastasis Rev; 2021 Sep; 40(3):777-789. PubMed ID: 34455517
[TBL] [Abstract][Full Text] [Related]
4. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer.
Khomiak A; Brunner M; Kordes M; Lindblad S; Miksch RC; Öhlund D; Regel I
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33147766
[TBL] [Abstract][Full Text] [Related]
5. Five key lncRNAs considered as prognostic targets for predicting pancreatic ductal adenocarcinoma.
Song J; Xu Q; Zhang H; Yin X; Zhu C; Zhao K; Zhu J
J Cell Biochem; 2018 Jun; 119(6):4559-4569. PubMed ID: 29239017
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians.
Giannis D; Moris D; Barbas AS
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33802340
[TBL] [Abstract][Full Text] [Related]
7. The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer.
Abdul Rahman R; Lamarca A; Hubner RA; Valle JW; McNamara MG
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359684
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review.
Wang Y; Zhong X; Zhou L; Lu J; Jiang B; Liu C; Guo J
Front Oncol; 2020; 10():1466. PubMed ID: 33042793
[No Abstract] [Full Text] [Related]
9. The Landscape of Microbial Composition and Associated Factors in Pancreatic Ductal Adenocarcinoma Using RNA-Seq Data.
Yu D; Wang T; Liang D; Mei Y; Zou W; Guo S
Front Oncol; 2021; 11():651350. PubMed ID: 34136388
[TBL] [Abstract][Full Text] [Related]
10. Body site-dependent variations of microbiota in pancreatic cancer pathophysiology.
Panebianco C; Pazienza V
Crit Rev Clin Lab Sci; 2019 Jun; 56(4):260-273. PubMed ID: 31060399
[TBL] [Abstract][Full Text] [Related]
11. Challenges in precision medicine in pancreatic cancer: A focus in cancer stem cells and microbiota.
Perelló-Reus CM; Rubio-Tomás T; Cisneros-Barroso E; Ibargüen-González L; Segura-Sampedro JJ; Morales-Soriano R; Barceló C
Front Oncol; 2022; 12():995357. PubMed ID: 36531066
[TBL] [Abstract][Full Text] [Related]
12. microRNA based prognostic biomarkers in pancreatic Cancer.
Guo S; Fesler A; Wang H; Ju J
Biomark Res; 2018; 6():18. PubMed ID: 29942514
[TBL] [Abstract][Full Text] [Related]
13. Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma.
Jiang K; Tan E; Sayegh Z; Centeno B; Malafa M; Coppola D
Appl Immunohistochem Mol Morphol; 2017 Oct; 25(9):620-623. PubMed ID: 27093451
[TBL] [Abstract][Full Text] [Related]
14. The Microbiome in PDAC-Vantage Point for Future Therapies?
Pfisterer N; Lingens C; Heuer C; Dang L; Neesse A; Ammer-Herrmenau C
Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497456
[TBL] [Abstract][Full Text] [Related]
15. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2017 Apr; 40(2):181-192. PubMed ID: 28205147
[TBL] [Abstract][Full Text] [Related]
16. The microbiota and microbiome in pancreatic cancer: more influential than expected.
Wei MY; Shi S; Liang C; Meng QC; Hua J; Zhang YY; Liu J; Zhang B; Xu J; Yu XJ
Mol Cancer; 2019 May; 18(1):97. PubMed ID: 31109338
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
Brunetti O; Russo A; Scarpa A; Santini D; Reni M; Bittoni A; Azzariti A; Aprile G; Delcuratolo S; Signorile M; Gnoni A; Palermo L; Lorusso V; Cascinu S; Silvestris N
Oncotarget; 2015 Sep; 6(27):23323-41. PubMed ID: 26259238
[TBL] [Abstract][Full Text] [Related]
18. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
[TBL] [Abstract][Full Text] [Related]
19. Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma.
Li H; Wang X; Fang Y; Huo Z; Lu X; Zhan X; Deng X; Peng C; Shen B
Oncotarget; 2017 Aug; 8(32):52571-52583. PubMed ID: 28881752
[TBL] [Abstract][Full Text] [Related]
20. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
